OptimizeRx stock expands access to 800,000 providers remains below its yearly high lacks? no
OptimizeRx (OPRX) stock was trading at $8.64 on October 5, 2026, despite its OpenPath network expanding access to 800,000 healthcare professionals. The company reported a significant Q2 revenue decline of 29.8% to $20.504 million, resulting in a net loss, though gross margin remained high at 76.5%. Analysts maintain a "Moderate Buy" consensus with an average 12-month price target of $11.43, even as the stock trades substantially below its 52-week high.
Form 4 OPTIMIZERx Corp For: 2 October By Investing.com
This article announces the Form 4 filing for OPTIMIZERx Corp on October 2nd. The content is brief, primarily serving as an announcement for this regulatory filing, and includes general market data and related articles from Investing.com. It highlights OPTIMIZERx Corp with its stock symbol OPRX and a recent performance of +3.16%.
Form 4 OPTIMIZERx Corp For: 2 October By Investing.com
This article announces the filing of Form 4 for OPTIMIZERx Corp on October 2, 2026. Form 4 is a U.S. Securities and Exchange Commission filing used to disclose changes in beneficial ownership of a company's securities by insiders. The article, published by Investing.com, provides no further details beyond this announcement.
Stock vesting triggers tax withholding at OptimizeRx (OPRX): 414 shares at $8.39 each.
OptimizeRx's Chief Business Officer, Andrew J. D'Silva, had 414 shares withheld on October 1, 2026, to cover tax withholding obligations upon the vesting of restricted stock units. Each share was valued at $8.39, and his direct holdings after this transaction totaled 99,246 shares. This event is classified as a disposition of securities under Section 16 of the Securities Exchange Act.
Learn Why The Bull Case For Trade Desk Stock Could Change Following Healthcare Ad Access Expansion
The Trade Desk (TTD) recently integrated with OptimizeRx’s OpenPath, allowing advertisers programmatic access to healthcare point-of-care inventory across 400+ EHR systems, reaching 800,000 healthcare professionals. While this offers differentiated supply, it's unlikely to immediately offset challenges like declining revenue/earnings forecasts and management changes. The article suggests this expanded access could significantly impact Trade Desk's investment narrative long-term, especially if AI acts as an additional catalyst, but near-term focus remains on stabilizing core business performance.
Squarepoint Ops LLC Sells 132,507 Shares of OptimizeRx Corp. $OPRX
Squarepoint Ops LLC significantly reduced its stake in OptimizeRx Corp. (NASDAQ: OPRX) by 74.6% in the second quarter, selling 132,507 shares and retaining 45,064. Despite this sale, institutional investors collectively own 76.47% of OPRX, and analysts generally maintain a "Moderate Buy" rating with a consensus price target of $11.43. OptimizeRx recently reported strong earnings, exceeding analyst expectations for both EPS and revenue.
OptimizeRx Expands Authenticated HCP Reach on The Trade Desk
OptimizeRx Corp. has announced an integration with OpenPath, The Trade Desk's supply path optimization solution, to expand its authenticated HCP reach. This partnership will allow advertisers using The Trade Desk direct access to OptimizeRx’s network of over 400 EHR and e-prescribe systems, reaching 800,000 verified healthcare professionals. The integration aims to streamline the process for life sciences marketers to incorporate point-of-care inventory into their programmatic media strategies, with availability expected in Q4 2026.
OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network
OptimizeRx (OPRX) has partnered with The Trade Desk (TTD) to integrate its point-of-care inventory with OpenPath, The Trade Desk’s supply path optimization solution. This integration will make OptimizeRx's healthcare ad network, which covers over 400 EHR and e-prescribe systems and reaches 800,000 healthcare professionals, directly available to advertisers through The Trade Desk’s demand-side platform. The move aims to expand programmatic access to EHR advertising, allowing advertisers to leverage existing programmatic buying infrastructure for healthcare inventory, with availability expected in Q4 2026.
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
The Trade Desk (TTD) is enhancing its presence in healthcare advertising through a new integration with OptimizeRx (OPRX), providing advertisers direct access to authenticated healthcare professional (HCP) inventory via TTD’s OpenPath platform. This partnership aims to simplify media planning for life sciences advertisers and integrate HCP-focused campaigns with broader programmatic strategies. The deal is expected to boost TTD's healthcare offerings, complementing its existing data and measurement capabilities, and potentially attracting more pharmaceutical advertisers.
OptimizeRx Corporation (OPRX) Stock Price, News, Quote & History
This article provides a comprehensive overview of OptimizeRx Corporation (OPRX), including its current stock price, financial performance, and historical data. It details the company's business model as a digital healthcare technology provider and offers key financial metrics, analyst insights, and comparisons to the S&P 500 benchmark. The information is presented to give investors a snapshot of OPRX's market position and operational health.
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
OptimizeRx will integrate its authenticated point-of-care inventory with The Trade Desk’s OpenPath in Q4 2026, enabling advertisers to programmatically access OptimizeRx's network of over 400 EHR and e-prescribe systems. This integration will reach approximately 800,000 verified healthcare professionals, bringing in-workflow EHR placements into mainstream programmatic buying for life sciences marketers. The move aims to expand programmatic distribution for OptimizeRx, offering advertisers greater flexibility and direct access to differentiated HCP inventory.
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
OptimizeRx announced an integration with OpenPath, The Trade Desk’s supply path optimization solution, to provide advertisers direct access to OptimizeRx’s network of over 400 EHR and e-prescribe systems, reaching 800,000 verified healthcare professionals (HCPs). This integration allows life sciences marketers to incorporate OptimizeRx's point of care inventory into broader programmatic media strategies, making EHR advertising inventory more accessible and transparent. The company expects this inventory to be available through OpenPath in the fourth quarter of 2026, aiming to expand programmatic distribution for its EHR network.
OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network
OptimizeRx announced an integration with OpenPath, The Trade Desk's supply path optimization solution, to make its authenticated point-of-care inventory directly available to advertisers. This partnership expands OptimizeRx's healthcare ad network, which spans over 400 EHR and e-prescribe systems, allowing advertisers to utilize The Trade Desk's programmatic buying infrastructure for healthcare inventory. The integration aims to broaden access for life sciences advertisers and is expected to be available in Q4 2026.
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Rating of "Moderate Buy" by Brokerages
OptimizeRx Corp. (NASDAQ:OPRX) has received a consensus "Moderate Buy" rating from nine analysts, with an average 12-month price target of $11.43, significantly higher than its current share price of $7.29. The company recently surpassed quarterly earnings expectations, reporting EPS of $0.16 and revenue of $20.50 million. Institutional investors hold a substantial 76.47% stake in OptimizeRx, with several increasing their positions.
One prompt now builds patient and doctor audiences. OptimizeRx expanded the tool.
OptimizeRx (OPRX) has expanded its AI-powered Natural Language Audience Builder (NLAB) to allow media planners to create both claims-grade healthcare professional (HCP) and privacy-safe direct-to-consumer (DTC) audiences using a single, plain-language workflow. This upgrade integrates the company’s Micro-Neighborhood® Targeting (MNT) audiences, transforming NLAB into a platform-agnostic, no-code tool for life sciences media planning. The expansion also adds new optimization and media planning functionality specific to the DTC landscape, including interactive breakdowns of audience quality and reach, and instant generation of media channel propensities and demographic insights.
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence
OptimizeRx has expanded its AI-powered Natural Language Audience Builder (NLAB) to allow media planners to create both HCP and direct-to-consumer (DTC) audiences from a single workflow. This enhancement integrates OptimizeRx’s Micro-Neighborhood® Targeting (MNT) audiences into NLAB, enabling comprehensive life sciences media planning. The update aims to streamline audience creation, improve precision for marketing campaigns, and facilitate the activation of these audiences across various media channels.
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence
OptimizeRx has expanded its Natural Language Audience Builder (NLAB) to allow media planners to create both healthcare professional (HCP) and direct-to-consumer (DTC) audiences using a single workflow. This integration of Micro-Neighborhood® Targeting (MNT) audiences within NLAB aims to streamline media planning for life sciences companies, enabling faster and more precise audience activation. The enhancement includes new optimization features specific to the DTC landscape, such as decile-based audience quality breakdowns and instant generation of media channel propensities, ultimately helping marketers achieve higher engagement and impact.
A 10th annual growth conference is set for New York, with OptimizeRx taking part.
OptimizeRx announced that its management will participate in the 10th Annual Lake Street Capital Best Ideas Growth Conference on September 10, 2026, in New York. The company, a healthcare technology provider, will highlight its AI-driven engagement platform for life science brands at the conference. OptimizeRx focuses on privacy-safe, patient-centric technology and partners with global pharmaceutical and life sciences companies.
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
OptimizeRx Corporation has appointed Troy Sarich, a seasoned pharmaceutical and healthcare executive with nearly 30 years of experience in commercialization, data, analytics, and AI, as a Company advisor. Sarich previously served as Chief Commercial Data Science Officer at Johnson & Johnson, where he focused on advancing scientific and commercial capabilities. His expertise will help OptimizeRx expand its technology solutions and enhance engagement between life sciences brands, healthcare providers, and patients.
OptimizeRx appoints Troy Sarich as company advisor By Investing.com
OptimizeRx Corp. (NASDAQ:OPRX) has announced the appointment of Troy Sarich as a company advisor. Sarich brings nearly 30 years of experience in global healthcare, life sciences, and pharmaceutical commercialization, having previously served as Chief Commercial Data Science Officer at Johnson & Johnson. In his new role, Sarich will support OptimizeRx's technology and data offerings, aligning with the company's mission to use data, AI, and digital technologies to improve commercial decision-making and audience engagement in the life sciences sector.
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
OptimizeRx Corporation has appointed Troy Sarich, a veteran in pharmaceutical commercialization and AI, as a Company advisor. Sarich, formerly Chief Commercial Data Science Officer at Johnson & Johnson, brings nearly 30 years of experience to help OptimizeRx accelerate innovation and strengthen its life sciences marketing technology. His expertise in data, analytics, and artificial intelligence will support the company's goal of enhancing engagement between life sciences brands, healthcare providers, and patients.
OptimizeRx appoints Troy Sarich as company advisor
OptimizeRx Corp. (NASDAQ:OPRX) has appointed Troy Sarich as a company advisor, leveraging his nearly 30 years of experience in global healthcare, life sciences, and pharmaceutical commercialization. Sarich, formerly Chief Commercial Data Science Officer at Johnson & Johnson, will support OptimizeRx's technology and data offerings, focusing on data analytic solutions for patient and commercial outcomes. His expertise in data, AI, and digital technologies aligns with OptimizeRx's mission to provide healthcare technology solutions to life sciences companies.
OptimizeRx Corp. (NASDAQ:OPRX) Given Average Rating of "Moderate Buy" by Analysts
Analysts have assigned OptimizeRx Corp. (NASDAQ:OPRX) an average rating of "Moderate Buy," with a consensus 12-month price target of $11.43, significantly above its current trading price. The company recently surpassed earnings expectations, reporting $0.16 EPS against an $0.11 consensus and revenues of $20.5 million. Institutional investors hold a substantial 76.47% stake in OptimizeRx, with several increasing their positions.
OptimizeRx (NASDAQ: OPRX) insider logs new stock trade
OptimizeRx Chief Business Officer Andrew J. D'Silva reported an acquisition of 57,600 shares of common stock through a restricted stock unit grant. The shares, valued at $0.00 each, will vest in three equal annual installments starting August 20, 2027. Following this transaction, D'Silva directly holds 101,092 shares of OptimizeRx common stock.
OptimizeRx (NASDAQ: OPRX) COO keeps 25,187 shares after RSU tax withholding
OptimizeRx Corp (OPRX) Chief Operating Officer Brendan W. Merrell reported an insider transaction where 1,020 shares of common stock were withheld for tax obligations upon the vesting of restricted stock units on August 21, 2026, at $7.71 per share. This withholding is considered a disposition under Section 16, and Merrell now directly holds 25,187 shares. The transaction has a neutral impact and sentiment according to the filing summary.
OPRX|OptimizeRx Corp|Price:7.710|Chg%:-0.250
This article provides a detailed overview of OptimizeRx Corp (OPRX) stock, including live price, performance metrics, key financial figures, and analyst ratings. It highlights the company's recent Q2 2026 earnings call where revenue fell by 30% but guidance was reaffirmed, and details the company's healthcare technology platform leveraging AI. The report also lists major shareholders and frequently asked questions about the stock.
Citizens raises OptimizeRx stock price target on macro stability
Citizens has increased its price target for OptimizeRx (NASDAQ: OPRX) shares to $11.00 from $9.00, maintaining a Market Outperform rating. The upward revision is attributed to a more stable macroeconomic environment and the anticipated return of a major customer in late 2026 or 2027, alongside continued momentum in mid-tier biopharmas. The new target reflects an 8x 2026 EBITDA multiple, up from 7x, based on improved conviction in future financial estimates and the company's strategic initiatives.
OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital
Kennedy Capital Management LLC has reported a beneficial ownership of 1,248,899 shares of OptimizeRx Corp (OPRX) common stock, representing a 6.7% stake. The firm, based in St. Louis, Missouri, holds sole voting and dispositive power over these shares, establishing itself as a significant institutional investor in OptimizeRx. This disclosure was made through a Schedule 13G filing, indicating a passive investment.
Citizens raises OptimizeRx stock price target on macro stability
Citizens has increased its price target for OptimizeRx (NASDAQ:OPRX) to $11.00 from $9.00, maintaining a Market Outperform rating. This adjustment is based on a stabilizing macro environment, the potential return of a large customer, and momentum in mid-tier biopharma. The new target reflects an 8x 2026 EBITDA multiple, up from 7x, with the company’s DSP strategy and new solutions expected to drive growth in 2027.
Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX
Renaissance Technologies LLC significantly increased its stake in OptimizeRx Corp. (NASDAQ:OPRX) by 633.2% in the first quarter, now holding 216,856 shares valued at $1.36 million. OptimizeRx reported strong Q2 earnings, beating analyst estimates with $0.16 EPS and $20.5 million in revenue, and maintained its 2026 revenue guidance. Despite some revenue headwinds and a CFO transition, analysts have a "Moderate Buy" rating with an average price target of $13.14.
Stifel cuts OptimizeRx stock price target on revenue headwinds
Stifel has lowered its price target for OptimizeRx (NASDAQ:OPRX) to $12 from $14, while maintaining a Buy rating, due to revenue headwinds. OptimizeRx reported a 30% year-over-year revenue decline in Q2, attributed to client-specific issues, de-emphasis of acquired services, and macro challenges, though EBITDA margins expanded. The company reiterated its 2026 guidance for a low-double-digit revenue decline and mid-20s EBITDA margins, suggesting a transition year with anticipated sequential growth in the second half.
OptimizeRx (OPRX) revenue falls 21% as margins and cash flow hold
OptimizeRx (OPRX) reported a significant revenue decline of 21% year-to-date and 30% in Q2 2026, primarily due to the wind-down of a low-margin managed service program and the loss of revenue from a key customer. Despite this, the company improved its gross margin by shifting towards higher-margin solutions and maintained strong operating cash flow of $8.1 million in the first half of 2026. OptimizeRx also refinanced its debt, enhancing liquidity, but still faces a material weakness in internal control related to third-party data.
Stifel cuts OptimizeRx stock price target on revenue headwinds
Stifel has lowered its price target for OptimizeRx (NASDAQ: OPRX) to $12 from $14, while maintaining a Buy rating, due to significant revenue headwinds. The company reported a 30% year-over-year revenue decline in Q2 2026, though adjusted earnings per share exceeded expectations. OptimizeRx reiterated its 2026 guidance for a low-double-digit revenue decline, with analysts expecting a sales drop of 11% for the fiscal year.
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
OptimizeRx Corporation has announced key finance leadership changes, effective January 1, 2027. Andy D'Silva will become the new Chief Financial Officer, succeeding Ed Stelmakh, who will transition to a Strategic Advisor role. Heather Favazza has been appointed Chief Accounting Officer, reflecting the company's strong succession planning and confidence in its long-term strategy.
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
OptimizeRx has announced significant finance leadership appointments, effective January 1, 2027, as part of its succession planning. Andy D’Silva will take over as Chief Financial Officer, succeeding Ed Stelmakh, who will transition to a Strategic Advisor role. Heather Favazza has been appointed Chief Accounting Officer, reflecting the company's strong leadership bench and continued focus on financial rigor and growth strategy.
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ...
OptimizeRx Corp (OPRX) reported a 30% year-over-year revenue decrease in Q2 2026, reaching $20.5 million, with adjusted EBITDA falling to $4.1 million. Despite these revenue headwinds, the company exceeded consensus expectations, driven by strong growth in AI-enabled software and product innovations. OptimizeRx reaffirmed its full-year 2026 guidance, focusing on debt reduction, strategic product launches, and expanding into new market segments to drive future growth.
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
OptimizeRx Corp. announced its second-quarter 2026 financial results, reporting $20.5 million in revenue and reaffirming its fiscal year 2026 revenue guidance of $95 million to $100 million. The company also highlighted strategic platform advancements, including integrations with DeepIntent, the launch of Natural Language Audience Builder, and CopayCue, alongside significant debt reduction efforts. Despite a year-over-year revenue decrease, OptimizeRx expressed confidence in its operating model and future growth opportunities.
OptimizeRx names Andy D’Silva as CFO, Heather Favazza as CAO
OptimizeRx Corp. (NASDAQ:OPRX) has appointed Andy D’Silva as Chief Financial Officer and Heather Favazza as Chief Accounting Officer, effective January 1, 2027. D’Silva will succeed Ed Stelmakh, who transitions to a Strategic Advisor role after serving as CFO for five years during which the company expanded margins, refinanced debt, and completed an acquisition. The company stated this transition is part of its succession planning and its financial and growth strategy remains unchanged.
Earnings call transcript: OptimizeRx beats Q2 2026 profit view as shares slip
OptimizeRx Corp. reported Q2 2026 adjusted earnings of $0.16 per share, surpassing the $0.10 consensus, and revenue of $20.5 million, above the $20.19 million expectation. Despite beating profit views, the stock slipped after hours due to a 30% year-over-year revenue decline and continued pressure from large customer spending cuts. Management reaffirmed full-year 2026 guidance, expecting a stronger second half, and highlighted strategic shifts towards a broader platform for pharmaceutical marketers and increased recurring software revenue.
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx Corp. (OPRX) exceeded Q2 earnings and revenue estimates, reporting $0.16 per share against an expected $0.11, and revenues of $20.5 million, slightly above the consensus. Despite these positive results, the company's shares have underperformed the S&P 500 this year, with a Zacks Rank of #3 (Hold) indicating market-aligned performance in the near future. Investors are now looking to management's earnings call commentary and future estimate revisions for insights into the stock's direction.
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
OptimizeRx announced its second-quarter 2026 financial results, reporting $20.5 million in revenue and a GAAP net loss of $(0.7) million. Despite a year-over-year revenue decline, the company exceeded consensus expectations for revenue and adjusted EBITDA, which stood at $4.9 million. OptimizeRx reaffirmed its fiscal year 2026 revenue guidance of $95-$100 million and adjusted EBITDA guidance of $21-$25 million, citing recent platform advancements and strengthened customer engagement.
OptimizeRx CFO Ed Stelmakh Will Advise Through End of 2027
OptimizeRx (Nasdaq: OPRX) announced a planned finance leadership transition with Andy D’Silva appointed as the new Chief Financial Officer and Heather Favazza as Chief Accounting Officer, both effective January 1, 2027. Current CFO Ed Stelmakh will continue in his role through December 31, 2026, and then serve as a Strategic Advisor through the end of 2027 to ensure a smooth transition and continuity. The company credits Stelmakh with significant financial improvements and emphasizes that its financial and growth strategy remains unchanged.
OptimizeRx (OPRX) Q2 2026 revenue falls 30% but company reaffirms full-year outlook
OptimizeRx (OPRX) reported a 30% decrease in Q2 2026 revenue to $20.5 million and a GAAP net loss of $0.7 million, down from a net income of $1.5 million in Q2 2025. Despite the revenue decline and lower net revenue retention, the company reaffirmed its full-year 2026 guidance for revenue between $95-$100 million and adjusted EBITDA of $21-$25 million. OptimizeRx also announced a finance leadership transition, with Edward Stelmakh stepping down as CFO and Andy D’Silva and Heather Favazza taking over as CFO and Chief Accounting Officer, respectively, effective January 1, 2027.
Earnings To Watch: OptimizeRx Corp (OPRX) Q2 2026 -- GF Value Sees 106% Upside
OptimizeRx Corp (OPRX) is expected to release its Q2 2026 earnings soon, with consensus estimates predicting $20.20 million in revenue and an earnings per share of -$0.05. Despite recent declines in revenue and earnings estimates for 2026, analysts and GuruFocus see significant upside potential, with an average target price of $12.40 and a GF Value suggesting a 106.13% upside. The company's average brokerage recommendation is "Outperform."
OptimizeRx Set to Report Q2 2026 Results With Analyst Targets Pointing to Over 80% Upside
OptimizeRx Corp (OPRX) is scheduled to report its Q2 2026 earnings on August 12, with analysts expecting revenue of $20.20 million and a loss of $0.05 per share. Despite recent downward revisions in full-year revenue estimates and a significant stock drop after its Q1 beat, analysts maintain a bullish outlook, with price targets suggesting an 81% to 106% upside. Investors will be watching for Q2 results and full-year guidance to see if the company can close the gap between its trading price and its perceived intrinsic value.
OptimizeRx Corp (OPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
OptimizeRx Corp (OPRX) has an earnings forecast score of 8.67, ranking 26th in the Software & IT Services industry. Analysts project an average price target of $24.00, with a consensus "Buy" rating based on 6 analysts. The company's expected revenue for the next quarter is $20.20 million, and its EPS for the next quarter is anticipated to be $0.12.
OptimizeRx Corp (OPRX) Stock News Today
This article provides current stock information for OptimizeRx Corp (OPRX), including its latest stock price, market capitalization, and P/E ratio. It indicates that more news and analysis for OPRX will be published soon.
Segall Bryant & Hamill LLC Invests $1.19 Million in OptimizeRx Corp. $OPRX
Segall Bryant & Hamill LLC has invested $1.19 million in OptimizeRx Corp. (NASDAQ: OPRX), acquiring 188,704 shares, which gives them a 1.01% stake in the company. Institutional investors now collectively own 76.47% of OptimizeRx, which recently exceeded quarterly earnings and revenue expectations. Analysts generally maintain a "Moderate Buy" rating for OptimizeRx, with an average price target of $13.43 despite some recent reductions.
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
OptimizeRx Corp. (NASDAQ:OPRX) has received a consensus "Moderate Buy" rating from brokerages, with six out of nine analysts recommending a buy, two a hold, and one a sell. The average 12-month price target is $13.43, despite several firms recently lowering their targets. The company reported strong quarterly earnings, beating consensus estimates for both EPS and revenue.
Optimizerx Stock Price Forecast. Should You Buy OPRX?
StockInvest.us has upgraded OptimizeRx Corporation (OPRX) to a "Buy Candidate" with a technical score of 2.73, up from a "Hold." The stock price increased by 8.26% on the last trading day, reaching $6.55, and is forecasted to rise 16.87% over the next three months. Despite some mixed signals like a recent pivot top and falling volume on increasing price, the stock holds positive buy signals from both short and long-term Moving Averages.
